The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...

Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improves overall survival in patients with metastatic ...

Recent actions by the FDA and NIH in response to the current political climate have left key stakeholders in clinical trials ...

Sepehr Shojaei, VP of Design Solutions at Lightship, talks about how the company works with pharma and contract research ...

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Garty, chief technology officer, clinical data, Veeva Systems, discusses clinical data trends for 2025 and simplifying management ...

As clinical trial complexity, duration, and cost continue to rise, life sciences companies are turning to data to help them ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Shakthi Kumar, chief strategy & business officer, ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, chief strategy officer, Cluepoints, ...

With an increased need for operational efficiency, while also leveraging new technologies such as AI, the landscape of ...

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Patil, vice president, digital innovation, IQVIA, ...

Fortunately, we are making some progress as organizations such as the Partnership for Advancing Clinical Trials (PACT) ...

The long-held practice is effective in pinpointing the emergence of known and unknown risks to clinical development, study ...